General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Editas Medicine(MODEST), Lipigon Pharmaceuticals Inc.(MODEST), New Amsterdam(MODEST), Novartis(SIGNIFICANT), Avilar Therapeutics(MODEST), Amgen Inc.(SIGNIFICANT), Intercept Pharmaceuticals Inc.(MODEST), Life Extension(MODEST), Rona Therapeutics, Inc.(MODEST), GSK(MODEST), Organon(MODEST), Rona Therapeutics, Inc.(MODEST) EQUITY INTERESTS/STOCK OPTIONS: MediMergent LLC(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Wolters Kluwer(SIGNIFICANT)

View Full Disclosure